Personalised home hazard assessments and interventions will help to prevent older and at-risk people from suffering from falls, according to new NICE guideline ...

There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Tools to help you put the guidance into practice.

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technology being evaluated. If it is ...

Coding and clinical classification codes for this guidance. This guidance replaces NICE interventional procedures guidance on balloon disimpaction of the baby’s head at emergency caesarean during the ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

The technology, which is capable of movements more precise than the human hand, has the potential to transform care for patients being operated on by surgeons in specialist NHS centres. Patient ...

Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.

Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'. The ...

In development GID-IND10299 Expected publication date: TBC Register as a stakeholder ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...